461 related articles for article (PubMed ID: 9516128)
1. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes.
Chavakis T; Kanse SM; Yutzy B; Lijnen HR; Preissner KT
Blood; 1998 Apr; 91(7):2305-12. PubMed ID: 9516128
[TBL] [Abstract][Full Text] [Related]
2. Urokinase-dependent human vascular smooth muscle cell adhesion requires selective vitronectin phosphorylation by ectoprotein kinase CK2.
Stepanova V; Jerke U; Sagach V; Lindschau C; Dietz R; Haller H; Dumler I
J Biol Chem; 2002 Mar; 277(12):10265-72. PubMed ID: 11756447
[TBL] [Abstract][Full Text] [Related]
3. The urokinase receptor is a major vitronectin-binding protein on endothelial cells.
Kanse SM; Kost C; Wilhelm OG; Andreasen PA; Preissner KT
Exp Cell Res; 1996 May; 224(2):344-53. PubMed ID: 8612711
[TBL] [Abstract][Full Text] [Related]
4. Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization.
Sidenius N; Andolfo A; Fesce R; Blasi F
J Biol Chem; 2002 Aug; 277(31):27982-90. PubMed ID: 12034711
[TBL] [Abstract][Full Text] [Related]
5. Interaction of single-chain urokinase with its receptor induces the appearance and disappearance of binding epitopes within the resultant complex for other cell surface proteins.
Higazi AA; Upson RH; Cohen RL; Manuppello J; Bognacki J; Henkin J; McCrae KR; Kounnas MZ; Strickland DK; Preissner KT; Lawler J; Cines DB
Blood; 1996 Jul; 88(2):542-51. PubMed ID: 8695802
[TBL] [Abstract][Full Text] [Related]
6. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system.
Stahl A; Mueller BM
Int J Cancer; 1997 Mar; 71(1):116-22. PubMed ID: 9096674
[TBL] [Abstract][Full Text] [Related]
7. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction.
Høyer-Hansen G; Behrendt N; Ploug M; Danø K; Preissner KT
FEBS Lett; 1997 Dec; 420(1):79-85. PubMed ID: 9450554
[TBL] [Abstract][Full Text] [Related]
8. The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.
Salasznyk RM; Zappala M; Zheng M; Yu L; Wilkins-Port C; McKeown-Longo PJ
Matrix Biol; 2007 Jun; 26(5):359-70. PubMed ID: 17344041
[TBL] [Abstract][Full Text] [Related]
9. A soluble form of the urokinase plasminogen activator receptor (suPAR) can bind to hematopoietic cells.
Mizukami IF; Todd RF
J Leukoc Biol; 1998 Aug; 64(2):203-13. PubMed ID: 9715260
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.
Czekay RP; Aertgeerts K; Curriden SA; Loskutoff DJ
J Cell Biol; 2003 Mar; 160(5):781-91. PubMed ID: 12615913
[TBL] [Abstract][Full Text] [Related]
11. Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase.
Chang AW; Kuo A; Barnathan ES; Okada SS
Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1855-60. PubMed ID: 9848876
[TBL] [Abstract][Full Text] [Related]
12. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor.
Colman RW; Pixley RA; Najamunnisa S; Yan W; Wang J; Mazar A; McCrae KR
J Clin Invest; 1997 Sep; 100(6):1481-7. PubMed ID: 9294114
[TBL] [Abstract][Full Text] [Related]
13. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration.
Yebra M; Parry GC; Strömblad S; Mackman N; Rosenberg S; Mueller BM; Cheresh DA
J Biol Chem; 1996 Nov; 271(46):29393-9. PubMed ID: 8910604
[TBL] [Abstract][Full Text] [Related]
14. Sequences within domain II of the urokinase receptor critical for differential ligand recognition.
Li Y; Lawrence DA; Zhang L
J Biol Chem; 2003 Aug; 278(32):29925-32. PubMed ID: 12761227
[TBL] [Abstract][Full Text] [Related]
15. Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.
Olson D; Pöllänen J; Høyer-Hansen G; Rønne E; Sakaguchi K; Wun TC; Appella E; Danø K; Blasi F
J Biol Chem; 1992 May; 267(13):9129-33. PubMed ID: 1315748
[TBL] [Abstract][Full Text] [Related]
16. Release of soluble urokinase receptor from vascular cells.
Chavakis T; Willuweit AK; Lupu F; Preissner KT; Kanse SM
Thromb Haemost; 2001 Aug; 86(2):686-93. PubMed ID: 11522023
[TBL] [Abstract][Full Text] [Related]
17. Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading.
Planus E; Barlovatz-Meimon G; Rogers RA; Bonavaud S; Ingber DE; Wang N
J Cell Sci; 1997 May; 110 ( Pt 9)():1091-8. PubMed ID: 9175705
[TBL] [Abstract][Full Text] [Related]
18. Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor.
Høyer-Hansen G; Pessara U; Holm A; Pass J; Weidle U; Danø K; Behrendt N
Biochem J; 2001 Sep; 358(Pt 3):673-9. PubMed ID: 11535128
[TBL] [Abstract][Full Text] [Related]
19. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
Quax PH; Grimbergen JM; Lansink M; Bakker AH; Blatter MC; Belin D; van Hinsbergh VW; Verheijen JH
Arterioscler Thromb Vasc Biol; 1998 May; 18(5):693-701. PubMed ID: 9598826
[TBL] [Abstract][Full Text] [Related]
20. Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143).
Huang M; Mazar AP; Parry G; Higazi AA; Kuo A; Cines DB
Acta Crystallogr D Biol Crystallogr; 2005 Jun; 61(Pt 6):697-700. PubMed ID: 15930623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
